Methylprednisolone EP Impurity D；1338549-02-2
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: M038025
English Name: Methylprednisolone EP Impurity D
English Alias: 2-hydroxy-2-((6S,8S,9S,10R,11S,13S,14S)-11-hydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,13,15,16-octahydro-3H-cyclopenta[a]phenanthren-17(6H,10H,14H)-ylidene)acetaldehyde
CAS Number: 1338549-02-2
Molecular Formula: C₂₂H₂₈O₄
Molecular Weight: 356.46
As a specific impurity of Methylprednisolone (EP-specified), this compound has the following advantages:
Well-defined with distinct stereochemistry: Contains a steroidal cyclopenta[a]phenanthrene core, 11-hydroxy, 3-oxo, chiral centers (6S,8S, etc.), and a 17-hydroxyl aldehyde ylidene side chain (-C(OH)(CHO)=). Unlike methylprednisolone (17-hydroxymethyl), its hydroxyl-aldehyde-double bond synergy creates significant polarity differences, enabling clear differentiation via reversed-phase HPLC/LC-MS as a specific marker;
High stability and traceability: Rigid steroidal tetracyclic structure ensures stability under neutral conditions. As a byproduct of abnormal 17-side chain oxidation/isomerization, it directly reflects side chain modification selectivity, improving process tracing accuracy;
High detection sensitivity: Strong UV absorption (230-250nm) from steroidal conjugation and aldehyde activity, combined with m/z 357 [M+H]⁺, enables ppb-level trace analysis via LC-MS, compatible with steroidal hydroxyl-aldehyde ylidene impurity systems.
Pharmaceutical quality control: Used as an EP reference standard to quantify Methylprednisolone EP Impurity D in APIs/formulations, ensuring compliance with EP standards for 17-side chain impurities;
Synthesis optimization: Optimizing 17-side chain reduction (catalyst selectivity) by monitoring impurity levels to enhance target hydroxymethyl formation;
Impurity profile enrichment: Supporting regulatory filings by supplementing methylprednisolone’s impurity profile to meet international pharmacopoeial requirements.
Methylprednisolone, a glucocorticoid, relies on 11-hydroxy and 17-hydroxy for anti-inflammatory activity, requiring precise 17-side chain reduction control. Abnormal oxidation or double bond isomerization at C17 may generate hydroxyl aldehyde ylidene derivatives like Methylprednisolone EP Impurity D. Pharmacologically inactive and listed as a controlled impurity in EP, its control is critical for methylprednisolone quality assurance.
Current research focuses on:
Analytical method validation: Developing UPLC-DAD assays with C18 columns for baseline separation, achieving 0.05% quantitation limits per EP standards;
Side chain isomerization kinetics: Studying impurity formation under varying pH to clarify 17-double bond-hydroxyl synergy mechanisms;
Process refinement: Controlling impurity levels below 0.1% via optimized catalyst dosage to meet EP specifications;
Structural confirmation: Using 2D-NMR to verify 17-hydroxyl aldehyde ylidene configuration, distinguishing from methylprednisolone for authoritative identification
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
China
